Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Iris Isufi"'
Autor:
Jonathan Avery, Namrata Chandhok, Chanelle Rainey, Richard Torres, Scott Huntington, Iris Isufi, Stuart Seropian, Mina L Xu, Francine Foss
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:680-689
Peripheral T-Cell Lymphomas (PTCL) are a rare subgroup of lymphomas with a poor outcome.Traditional prognostic measures rely heavily on disease stage, and with the advent of targeted treatment, further stratificationcriteria are needed to guide treat
Autor:
Ahmad S. Halwani, Carlos Panizo, Iris Isufi, Alex F. Herrera, Craig Y. Okada, Elizabeth H. Cull, Bela Kis, Jorge M. Chaves, Nancy L. Bartlett, Weiyun Ai, Luis de la Cruz-Merino, Locke J. Bryan, Roch Houot, Kim Linton, Javier Briones, Ian Chau, Gottfried R. von Keudell, Hailing Lu, Adam Yakovich, Michael Chen, ter Meulen JH, Sergey Yurasov, Frank J. Hsu, Christopher R. Flowers
Publikováno v:
Leukemia & lymphoma
Leukemia & lymphoma, Taylor & Francis, 2021, ⟨10.1080/10428194.2021.2010057⟩
Leukemia & lymphoma, 2022, 63 (4), pp.821-833. ⟨10.1080/10428194.2021.2010057⟩
LEUKEMIA & LYMPHOMA
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Leukemia & lymphoma, Taylor & Francis, 2021, ⟨10.1080/10428194.2021.2010057⟩
Leukemia & lymphoma, 2022, 63 (4), pp.821-833. ⟨10.1080/10428194.2021.2010057⟩
LEUKEMIA & LYMPHOMA
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
International audience; Intratumoral injection of G100, a toll-like receptor 4 (TLR4) agonist, was shown pre-clinically to stimulate anti-tumor immune responses and tumor regression. This open-label, multicenter, phase 1/2 trial evaluated the safety,
Autor:
Madiha Iqbal, Han Tun, Erel Joffe, Christian Grommes, Grzegorz Nowakowski, Matthew Lunning, Radhakrishnan Ramchandren, Chia-Cheng Li, Wanying Zhao, Elizabeth Martinez, Reinhard von Roemeling, Robert Earhart, Meaghan McMahon, Iris Isufi, Lori Leslie, Allison Rosenthal
Publikováno v:
Neuro-Oncology. 24:vii68-vii69
BACKGROUND Emavusertib, an oral interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, targets toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathway in B-cell proliferation. IRAK4 forms a Myddosome complex with MYD88 ad
Autor:
Amy J. Davidoff, Cary P. Gross, Scott F. Huntington, Shalin Kothari, Iris Isufi, Kishan Patel
Publikováno v:
Blood. 136:1946-1955
The ALLIANCE A041202 trial found that continuously administered ibrutinib in the first-line setting significantly prolonged progression-free survival compared with a fixed-duration treatment of rituximab and bendamustine in older adults with chronic
Autor:
Rory M. Shallis, Stuart Seropian, Amer M. Zeidan, Nikolai A. Podoltsev, Steven D. Gore, Lohith Gowda, Karl Hager, Tae Kon Kim, Jan Philipp Bewersdorf, Iris Isufi, Alexa J. Siddon, Manoj M. Pillai, Wei Wei
Publikováno v:
Leuk Lymphoma
Mutations in the tumor suppressor gene TP53 are detected in 5–10% of patients with acute myeloid leukemia (AML) and myelodysplastic syndromes. TP53 mutations have been associated with complex karyotypes, therapy-related malignancies, lower response
Autor:
Sourish Saha, Tycel Phillips, Christopher R. Flowers, Lisa Musick, Christopher Arthur, Rajat Bannerji, Paula Marlton, Iris Isufi, Sam Yuen, Brandon Croft, Paolo Corradini, Robert Emmons, Annalia Molinari, Jamie Hirata, Giuseppe Gritti, John F. Seymour
Publikováno v:
Hematological Oncology. 39
7534 Background: Polatuzumab vedotin (Pola) + obinutuzumab (G) demonstrated activity and tolerability in a Phase 1b/2 trial of patients (pts) with R/R FL (Phillips, et al. Blood 2016). Preclinical studies with venetoclax (Ven) showed that concurrent
Autor:
Erel Joffe, Grzegorz S. Nowakowski, Han W. Tun, Allison Claire Rosenthal, Matthew Alexander Lunning, Radhakrishnan Ramchandren, Chia-Cheng Li, Li Zhou, Elizabeth Martinez, Reinhard W. Von Roemeling, Robert H. Earhart, Meaghan McMahon, Iris Isufi, Lori Ann Leslie
Publikováno v:
Journal of Clinical Oncology. 40:7575-7575
7575 Background: CA-4948 is a novel oral inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4), which is essential for toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling in B cell proliferation. IRAK4 forms a Myddosome co
Publikováno v:
Leuk Lymphoma
A recent phase II trial showed that use of polatuzumab vedotin in combination with bendamustine plus rituximab (Pola-BR) in transplant-ineligible patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) resulted in longer prog
Autor:
Michael Girardi, Lynn D. Wilson, Stuart Seropian, Francine M. Foss, Sarah Perreault, Kenneth B. Roberts, Lohith Gowda, Iris Isufi
Publikováno v:
Leukemialymphoma. 61(12)
We report results on 23 patients with cutaneous T cell lymphoma (7 primary cutaneous γδ T cell lymphoma [PCGDT], 16 mycosis fungoides/Sézary syndrome [MF/SS]) who underwent allogeneic stem cell transplantation. All pts had skin involvement, 14 had
Autor:
Ami N. Rubinowitz, Sheela V Shenoi, Sarah Perreault, Marie L. Landry, Lohith Gowda, Stuart Seropian, Iris Isufi, Francine M. Foss
Publikováno v:
Clinical Lymphoma, Myeloma & Leukemia
Clinical Lymphoma Myeloma and Leukemia
Clinical Lymphoma Myeloma and Leukemia
Severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) has a high death rate in patients with comorbidities or in an immunocompromised state. We report a mild and attenuated SARS CoV-2 infection in a patient who is 17 months post stem cell tran